A practical reference on dual agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-10-09. Anything still debated is marked as such rather than presented as settled.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
固体状态的 tirzepatide 通常以冻干粉形式保存，推荐在低温、避光、干燥条件下存放，常见区间为 2 至 8 摄氏度，长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出，从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。
溶解操作一般使用注射用水或适宜的水性缓冲液，必要时加入少量助溶剂以改善溶解速度，但应避免剧烈涡旋振荡，因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态，具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分，则取决于用途是否为多次取样。
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
=== 1995 === 9 January Beyond Love, an Equinox Special about autoerotic asphyxia, which killed over 50 people in 1994; and due to the deeply, and distasteful, unconventional content of the programme, it was shown at 10pm; at the Johns Hopkins Sexual Disorders Clinic at the Johns Hopkins Bloomberg School of Public Health in Baltimore in Maryland, where chromosomal abnormality was found by Fred Berlin, often Klinefelter syndrome; Dr Raymond Goodman of Hope Hospital in Salford, now of the Institute of Brain, Behaviour and Mental Health at the University of Manchester, and why 90% of paraphiliacs were male; Peter Fenwick (neuropsychologist) of the Institute of Psychiatry, Psychology and Neuroscience, and how sexual arousal is centred in the limbic system; Gene Abel of the Behavioral Medicine Institute of Atlanta; William Marshall of the Queen's University at Kingston; Jeffrey Weeks (sociologist) at London South Bank University; John Bancroft (sexologist) of the MRC Reproductive Biology Unit in Edinburgh; Stephen Hucker of Queen's University, Ontario; John Money of Johns Hopkins Hospital; forensic psychologist Ronald Langevin. Narrated by Dame Jenni Murray, directed by Peter Boyd Maclean, produced by Simon Andreae, made by Optomen Television 27 August The Real X-Files: America's Psychic Spies, an Equinox Special about a former American military unit that conducted remote viewing, where operatives could see backwards and forwards in time; Admiral Stansfield Turner, Director from 1977 to 1981 of the CIA; Major-General Ed Thompson; Colonel John B.
Alkanes with more than three carbon atoms can be arranged in various ways, forming structural isomers. The simplest isomer of an alkane is the one in which the carbon atoms are arranged in a single chain with no branches. This isomer is sometimes called the n-isomer (n for "normal", although it is not necessarily the most common). However, the chain of carbon atoms may also be branched at one or more points. The number of possible isomers increases rapidly with the number of carbon atoms. For example, for acyclic alkanes:
RGFP966, or RGFP-966, is a histone deacetylase (HDAC) inhibitor which is used in scientific research. It is a highly selective HDAC3 inhibitor. The drug is the most commonly used selective HDAC3 inhibitor in research.
== History == Cheesemaking is documented in Egyptian tomb drawings and in ancient Greek literature. Cheesemaking may have originated from nomadic herdsmen who stored milk in vessels made from sheep's and goats' stomachs. Because their stomach linings contain a mix of lactic acid, bacteria as milk contaminants and rennet, the milk would ferment and coagulate. A product reminiscent of yogurt would have been produced, which through gentle agitation and the separation of curds from whey would have resulted in the production of cheese; the cheese being essentially a concentration of the major milk protein, casein, and milk fat. The whey proteins, other major milk proteins, and lactose are all removed in the cheese whey. Another theory is offered by David Asher, who wrote that the origins actually lie within the "sloppy milk bucket in later European culture, it having gone unwashed and containing all of the necessary bacteria to facilitate the ecology of cheese".
The brand became a well-established franchise in the Philippines, where it began in 1975 under the ownership of the country's largest food conglomerate, San Miguel Corporation, primarily promoting their San Miguel draft beer. Beginning with a restaurant located on Makati Avenue in Makati, the restaurant expanded rapidly in Metro Manila, with most of its outlets offering live music. San Miguel had difficulty maintaining the consistency of the branches, and ultimately sold the franchise in 1987 to International Family Food Services, Inc. (IFFSI), a group led by the family of sports executive Leo Prieto. In 1997, it had evolved into mostly a fast-food franchise. The brand was reengineered as a family-oriented casual dining brand in 2003. In 2004, Shakey's partnered with Sports Vision for the launch of the Shakey's V-League, one of the pioneering volleyball leagues in the country. The Shakey's Super League was formally launched on August 16, 2022, at the Shakey's Pizza Aseana City outlet in Parañaque. This marks the return of Shakey's Pizza in Philippine volleyball since they served as the title sponsor for the Shakey's V-League (now Premier Volleyball League) from 2004 to 2017. As of early 2015, there were 153 Shakey's outlets in the Philippines, more than double the number remaining in the United States. In March 2016, the Century Pacific Group and the Singapore-based GIC Private Limited acquired the majority shares of IFFSI from the Prieto family, which will retain a minority interest in the company.
Sources: en.wikipedia.org
== Biology / Functions == Efficient presentation of antigenic peptides by MHC class I molecules provides the key signal for adaptive immune responses by cytotoxic (CD8+) T lymphocytes. In the "endogenous" antigen presentation pathway, proteins synthesized by cells undergo cytosolic degradation and some of their peptide fragments are transported to the ER, where suitable-length peptides are loaded onto MHC class I molecules. In the ER, ERAP1 shortens longer peptides to the optimal length for stable binding onto MHC class I molecules (Figure 1). ERAP1, like other APP components, is induced by interferon gamma, a cytokine inducing antigen presentation. ERAP1 preferentially trims N-extended substrates of 9-16 residues to optimally sized 8-10 residue peptides. This "molecular ruler" mechanism is unique to ERAP1. ERAP1 also functions in the presentation of extracellular antigens in the cross-presentation pathway. ERAP1 "trimming" modulates the peptide repertoire presented by MHC class I molecules and thereby shapes the adaptive immune response. In murine models, ERAAP (the murine homologue of human ERAP1) deficiency results in a strong alteration and increased immunogenicity of the peptide repertoire presented by MHC-I. Murine models with genetic deficiency for ERAAP have been instrumental for understanding the role of peptide trimming in the ER. Besides peptide trimming in the ER, ERAP1 has been proposed to perform additional functions depending on its location.
== Selected publications == Books Identification and Application of Phenotypic and Molecular Markers for Abiotic Stress Tolerance in Soybean, Berhanu Amsalu Fenta, Belen Marquez Garcia, Christine H. Foyer, Karl J. Kunert, Magdeleen DuPlessis, Urte Schluter: 2011. INTECH Open Access Publisher: ISBN 978-953-307-721-5 A New Era in Plant Metabolism Research Reveals a Bright Future for Bio-fortification and Human Nutrition, Christine H Foyer, Dean Dellapenna, Dominique Van der Straeten: 2006 Plant Carbon-nitrogen Interactions from Rhizosphere to Plant, Caroline Bowsher, Christine H Foyer, Society for Experimental Biology: Oxford University Press: 2004. Molecular Physiology: Engineering Crops for Hostile Environments, Martin A Parry, Christine H Foyer, Brian Forde: Oxford University Press: 2000. ISBN Causes of Photooxidative Stress and Amelioration of Defense Systems in Plants, Christine H Foyer, Philip M Mullineaux: CRC Press: 1994. ISBN 978-0-8493-5443-4 Photosynthesis, Christine H Foyer, Kreiger Publishing Co.: 1991 ISBN 978-0-89464-506-8 Research articles Foyer, Christine H.; Halliwell, Barry (1976). "The presence of glutathione and glutathione reductase in chloroplasts: a proposed role in ascorbic acid metabolism". Planta. 133 (1): 21–25. doi:10.1007/BF00386001. PMID 24425174. S2CID 27896738.
=== Television === Boodikka appears in the Duck Dodgers episode "The Green Loontern", voiced by Grey DeLisle. Boodikka makes a cameo appearance in the Justice League Action episode "Watchtower Tours".
=== Tigecycline === Tigecycline, a member of the glycylcyclines antibiotics, has proven to be an effective therapy against Enterobacteriaceae that typically display tetracycline resistance, because tigecycline has a higher binding affinity with ribosomal sites than tetracycline has. Tigecycline is capable of killing almost all of the ESBLs and multidrug-resistant (MDR) E. coli isolates and the large majority of ESBL and MDR isolates of Klebsiella species. A 2008 review of 42 studies of in vitro susceptibility of bacteria to tigecycline showed that MDR K. pneumoniae and E. coli, including those that were carbapenem resistant, were susceptible more than 90% of the time. A limited number of patients have been treated with tigecycline, but the FDA has approved it in certain cases with synergies of other drugs. The limited number of patients indicates that more trials are needed to determine the overall clinical effectiveness. Although tigecycline is one of the first lines of defense against carbapenemase-producing isolates, negative clinical outcomes with tigecycline have occurred. Both urinary tract and primary blood infections can make tigecycline ineffective, because it has limited penetration and rapid tissue diffusion after being intravenously infused, respectively.
Napoleon defeated the Prussians at Jena-Auerstedt and the Russians at Friedland, bringing an uneasy peace to the continent by July 1807, and again leaving Britain as France's sole major enemy. Britain was unable to dispute French dominance on the continent but obtained hegemony over the seas after victories including Trafalgar. Russia used the interim peace to resolve wars with the Ottomans, Swedes, and Iranians. Hoping to isolate and weaken Britain economically through his Continental System, Napoleon launched an invasion of Portugal, the only remaining British ally in continental Europe. After occupying Lisbon in November 1807, and with the bulk of French troops present in Spain, Napoleon seized the opportunity to turn against his former ally, depose the reigning Spanish royal family, and declare his brother as Joseph I the King of Spain in 1808, to the disapproval of the Spanish populace. Spain joined Britain and Portugal, with the three powers engaging France in the Peninsular War. The diversion of French armies to the large new Anglo-Spanish front led to Austria reentering the conflict and forming the Fifth Coalition in April 1809, composed of Austria, Spain, and Britain. Austria won the Battle of Aspern-Essling but was defeated at Wagram, forcing the imposition of a harsh peace in October 1809. Britain, Spain, and Portugal remained at war with France. Concurrently Russia, unwilling to bear the economic consequences of reduced trade, violated the Continental System, prompting Napoleon to launch an invasion in June 1812.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.